Matthew D. Falk

Acquired Resistance to Crizotinib from a Mutation in <i>CD74</i>–<i>ROS1</i>

Mark M. Awad, Ryohei Katayama, Michele McTigue et al. · New England Journal of Medicine · 2013 · 408 citations · Full text

Genome Instability, Same Resistance Mutation, Oncogenic Agent +14

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

Helen Y. Zou, Qiuhua Li, Lars D. Engstrom et al. · Proceedings of the National Academy of Sciences · 2015 · 267 citations · Full text

Inhibitory Activity, Radiation Oncology, Fusion Kinases +14

Discovery of a Novel Series of Inhibitors of Lymphoid Tyrosine Phosphatase with Activity in Human T Cells

Stephanie M. Stanford, Divya Krishnamurthy, Matthew D. Falk et al. · Journal of Medicinal Chemistry · 2011 · 58 citations · Full text

Drug Target, T-regulatory Cell, Immunology +22

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Hengmiao Cheng, Suvi T. M. Orr, Simon Bailey et al. · Journal of Medicinal Chemistry · 2020 · 39 citations · Full text

High-throughput screen using a single-cell tyrosine phosphatase assay reveals biologically active inhibitors of tyrosine phosphatase CD45

Stephanie M. Stanford, Rekha G. Panchal, Logan M. Walker et al. · Proceedings of the National Academy of Sciences · 2012 · 32 citations · Full text